KIYATEC

About

KIYATEC utilizes the patient’s own living tumor cells to create functional 3D models to test a battery of cancer therapies.

Greenville,South Carolina,United States
11 - 50
http://www.kiyatec.com

Highlights

Details

Last Funding Type: Series C
Last Funding Money Raised: $18M
Industries: Biotechnology,Health Diagnostics,Life Science
Founded date: Jan 1, 2005
Number Of Employee: 11 - 50
Operating Status: Active
Legal Name: KIYATEC Inc.

KIYATEC utilizes the patient’s own living tumor cells to create functional 3D models to test a battery of cancer therapies. Its 3DKUBE technology platform conveniently and cost-effectively incorporates perfusion flow, accommodates all scaffold materials, allows in situ imaging, models complex human biology using segregated cell co‐culture, and is a single-use disposable. 3DKUBE cell‐based assays leverage these features to create better in vitro prediction of complex biochemical responses in humans, with a focus on the evaluation of drug toxicity and efficacy prior to use in human clinical trials.

Funding Rounds

Number of Funding Rounds

Total Funding Amount

11

$30.94M

KIYATEC has raised a total of $30.94M in funding over 2 rounds. Their latest funding was raised on Dec 12, 2022 from a Series C round.

Announced Date	Round	Money Raised	Number of Investors	Lead Investors	Post Valuation
Dec 12, 2022	Series C	$18M	4	Bruker	—	Detail
Apr 30, 2021	Series Unknown	$2.50M	2	Seae Ventures	—	Detail
May 1, 2019	Series B	$3M	2	VentureSouth	—	Detail
Dec 15, 2017	Convertable Note	$2.20M	1	—	—	Detail
Dec 15, 2015	Series B	$2.85M	1	—	—	Detail